Aviado · Research
Longevity Daily
Monday, May 11, 2026
Listen
Today's Brief
Today's evidence points in two directions: NPR's must-read investigation finds that NAD+ marketing has dramatically outpaced human clinical data, even as researchers remain optimistic about the underlying biology. GLP-1 drugs continue to surprise — a blinded trial now shows significant Parkinson's motor benefits, while new mouse research links sleep apnea directly to vascular senescent cell accumulation. Northwestern researchers also cracked how metformin actually lowers blood sugar: the gut, not the liver, is doing the heavy lifting. Aviado Research rounds out the issue with a precise breakdown of when — and for whom — krill oil actually moves the needle on triglycerides.
10 stories7 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
GLP-1 Drugs Are Moving Beyond Diabetes — and the Brain Health Data Is Getting Serious
A double-blind, placebo-controlled trial (n=59) presented at the 2025 MDS Congress found that a GLP-1 receptor agonist produced significant improvements in Parkinson's-related motor function (p=.001) over 9 months — a result that has researchers rethinking these drugs' neurological ceiling. Beyond Parkinson's, GLP-1 receptor agonists are showing promise for stroke prevention through vascular risk reduction and possibly direct neuroprotection via independent brain mechanisms. If you or a family member has neurological risk factors, this expanding clinical picture is worth raising with your doctor.
Read more →Beyond the Gym: Creatine's Role in Brain Energy May Be Its Most Important Trick Yet
A new analysis highlights how creatine supplementation accelerates ATP regeneration in the brain, offering meaningful potential for supporting cognitive processing and neurological health as we age. The brain is one of the body's most energy-hungry organs, and ATP availability measurably declines with age — creatine's excellent safety profile, low cost, and decades of sports-nutrition research make it an easy addition to a brain-health protocol. Benefits appear most pronounced in older adults and vegetarians, who tend to have lower baseline brain creatine levels.
Read more →Your Gut Bacteria Can Turn Pomegranates and Berries Into Alzheimer's Protection — If You Have the Right Microbiome
A new review identifies urolithins — compounds gut bacteria produce from polyphenols in pomegranates, berries, and walnuts — as a promising mechanism for neuroprotection and Alzheimer's risk reduction. The catch: roughly 30–40% of people lack the gut bacteria needed to efficiently convert these polyphenols, making direct urolithin A supplementation a potentially important workaround for non-converters. This is a review paper, not a clinical trial, so treat it as strong mechanistic evidence rather than a confirmed intervention — but the gut-brain axis here is backed by solid preclinical data.
Read more →Supplements & Compounds
NPR's Deep Dive: NAD+ Infusions Are Booming — But Researchers Say the Human Evidence Is Thin
NPR's investigation finds that while NAD+ (nicotinamide adenine dinucleotide) is a genuinely interesting molecule in aging biology, researchers are alarmed that wellness marketers have translated early animal and cell data into confident claims about human longevity extension. The clinical picture in humans remains limited: most trials are small, short-term, and have not demonstrated the dramatic effects being sold — especially for IV infusions running $500–$1,000 per session. Scientists interviewed say they're frustrated watching their preliminary findings become marketing copy. If you're spending significantly on NAD+ products right now, the honest scientific consensus is that the biology is promising but the human proof-of-concept hasn't arrived yet.
Read more →Krill Oil Reliably Cuts Triglycerides — But Leaves Cholesterol Untouched: What That Tells You About Your Own Response
Across multiple high-quality studies, krill oil consistently lowers blood triglycerides but barely moves LDL or HDL cholesterol — making it one of the rare supplements with a single, trackable outcome you can confirm with a standard blood test. The practical protocol: take 2–4g daily with meals for 12 weeks, then test your triglycerides; a drop of at least 10 mg/dL signals you're a responder. If nothing moves, the evidence suggests continuing or increasing the dose won't help — and it's time to try a different strategy.
Read the full Aviado analysis →Research & Papers
An HIV Drug Just Reversed Epigenetic Aging Markers in the First Human Proof-of-Concept Trial
Researchers report that a drug originally developed for HIV appears to reverse key epigenetic aging markers in humans — described as the first such proof-of-concept trial in people. The proposed mechanism centers on silencing transposable elements, so-called 'genomic hitchhikers' that make up roughly 45% of human DNA and become increasingly active as we age, representing a fundamentally different approach from most current longevity interventions. The trial is small and results have not yet cleared peer review, so treat this as an early but genuinely novel signal rather than a confirmed finding.
Read more →Northwestern Researchers Reveal How Metformin Actually Works — and the Gut Is Doing the Heavy Lifting
A Northwestern University study found that metformin's blood sugar-lowering effects operate primarily through the gut: the drug inhibits mitochondrial complex I in intestinal epithelial cells, effectively turning the intestine into a glucose sink that burns extra sugar before it enters the bloodstream. This revises the prevailing liver-centric theory and opens the door to gut-targeted therapies with potentially fewer systemic side effects. For the many people taking metformin for type 2 diabetes or off-label longevity purposes, this mechanistic clarity helps explain the drug's reliable efficacy even at lower doses.
Read more →Lifestyle & Nutrition
Sleep Apnea Loads Your Blood Vessels With Senescent Cells — and Clearing Them Reverses the Damage
A new mouse study shows that the intermittent hypoxia caused by sleep apnea significantly increases the accumulation of senescent cells in vascular tissue, contributing directly to cardiovascular dysfunction. More compelling: clearing those senescent cells in the mice reversed the vascular damage, suggesting that senolytics — or simply treating sleep apnea aggressively — could undo part of this mechanism. If you snore heavily, wake unrefreshed, or have been told you stop breathing at night, this is a strong argument for formal sleep testing: unmanaged apnea may be quietly aging your arteries well ahead of your calendar age.
Read more →The World's Oldest Doctor Lived to 103 — His 3 Longevity Rules Challenge What the Optimization Crowd Preaches
Dr. Howard Tucker, a neurologist who held an active medical license until his death at 103, attributed his exceptional longevity to intellectual curiosity and continuous learning, a purpose-driven career he never fully retired from, and a mindset that embraced life's pleasures without obsession. His profile challenges the popular assumption that aggressive lifestyle optimization — strict diets, supplement stacks, rigid routines — is the defining factor in extreme longevity. While a single case is anecdote rather than data, his pattern aligns with robust research on cognitive engagement and sense of purpose as protective factors against neurological and systemic aging.
Read more →Industry & Policy
FDA Backs a Second Drug for Healthy Lifespan Extension in Dogs — and Longevity Researchers Are Paying Attention
The FDA has granted reasonable expectation of effectiveness to a second drug candidate aimed at extending healthy lifespan in senior dogs — a milestone that carries implications well beyond veterinary medicine. Dogs and humans share similar age-related disease trajectories, and regulatory acceptance of 'lifespan extension' as a therapeutic indication in any species helps legitimize the approval pathway for eventual human applications. The first such drug received analogous FDA support in 2024, suggesting a meaningful and accelerating shift in how regulators are willing to classify aging-related interventions.
Read more →